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Abstract 
Hybrid antimicrobials containing an antibacterial linked to a multidrug resistance (MDR) pump inhibitor 
make up a promising new class of agents for countering efflux-mediated bacterial drug resistance. This 
study explores the effects of varying the relative orientation of the antibacterial and efflux pump inhibitor 
components in three isomeric hybrids (SS14, SS14-M, and SS14-P) which link the antibacterial alkaloid 
and known substrate for the NorA MDR pump berberine to different positions on INF55 
(5-nitro-2-phenylindole), an inhibitor of NorA. The MICs for all three hybrids against wild-type, NorA-
knockout, and NorA-overexpressing Staphylococcus aureus cells were found to be similar (9.4 to 40.2 mu 
M), indicating that these compounds are not effectively effluxed by NorA. The three hybrids were also 
found to have similar curing effects in a Caenorhabditis elegans live infection model. Each hybrid was 
shown to accumulate in S. aureus cells to a greater extent than either berberine or berberine in the 
presence of INF55, and the uptake kinetics of SS14 were found to differ from those of SS14-M and 
SS14-P. The effects on the uptake and efflux of the NorA substrate ethidium bromide into S. aureus cells 
in the presence or absence of the hybrids were used to confirm MDR inhibition by the hybrids. MDR-
inhibitory activity was confirmed for SS14-M and SS14-P but not for SS14. Molecular dynamics 
simulations revealed that SS14 prefers to adopt a conformation that is not prevalent in either SS14-M or 
SS14-P, which may explain why some properties of SS14 diverge from those of its two isomers. In 
summary, subtle repositioning of the pump-blocking INF55 moiety in berberine-INF55 hybrids was found 
to have a minimal effect on their antibacterial activities but to significantly alter their effects on MDR 
pumps. 
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Hybrid antimicrobials containing an antibacterial linked to a multidrug resistance (MDR) pump inhibitor
make up a promising new class of agents for countering efflux-mediated bacterial drug resistance. This study
explores the effects of varying the relative orientation of the antibacterial and efflux pump inhibitor compo-
nents in three isomeric hybrids (SS14, SS14-M, and SS14-P) which link the antibacterial alkaloid and known
substrate for the NorA MDR pump berberine to different positions on INF55 (5-nitro-2-phenylindole), an
inhibitor of NorA. The MICs for all three hybrids against wild-type, NorA-knockout, and NorA-overexpressing
Staphylococcus aureus cells were found to be similar (9.4 to 40.2 M), indicating that these compounds are not
effectively effluxed by NorA. The three hybrids were also found to have similar curing effects in a Caenorhabditis
elegans live infection model. Each hybrid was shown to accumulate in S. aureus cells to a greater extent than
either berberine or berberine in the presence of INF55, and the uptake kinetics of SS14 were found to differ
from those of SS14-M and SS14-P. The effects on the uptake and efflux of the NorA substrate ethidium bromide
into S. aureus cells in the presence or absence of the hybrids were used to confirm MDR inhibition by the
hybrids. MDR-inhibitory activity was confirmed for SS14-M and SS14-P but not for SS14. Molecular dynamics
simulations revealed that SS14 prefers to adopt a conformation that is not prevalent in either SS14-M or
SS14-P, which may explain why some properties of SS14 diverge from those of its two isomers. In summary,
subtle repositioning of the pump-blocking INF55 moiety in berberine-INF55 hybrids was found to have a
minimal effect on their antibacterial activities but to significantly alter their effects on MDR pumps.
A key stimulus for current antibacterial research is the
emergence of multidrug-resistant (MDR) pathogenic bacte-
ria (10, 27, 30). Clinically relevant bacterial drug resistance
is often mediated through MDR efflux pumps in both Gram-
positive and Gram-negative bacteria (19, 28). MDR pumps
compromise the activity of structurally diverse antibiotics by
reducing their intracellular concentrations to subtoxic levels. In
response to this, many classes of small-molecule MDR inhib-
itors are being pursued for use as potentiators in combination
with antibiotics (16, 20, 21). A major disadvantage of the com-
bination approach is the challenge of matching the pharmaco-
kinetics and physicochemical properties of two structurally un-
related molecules. One promising alternative strategy is to
covalently link the pump inhibitor and the antibacterial agent
together into a single noncleavable hybrid molecule (2, 3, 9, 11,
31). Such hybrids carry the potential advantage of simulta-
neously delivering equimolar quantities of the two agents to
bacterial cells (5, 6) and avoiding the complications arising
from coadministration.
We previously reported on a prototype hybrid, SS14 (2),
containing the antibacterial alkaloid berberine with a sub-
stitution at its 13 position consisting of a noncleavable 2-
CH2 linkage to 5-nitro-2-phenyindole (INF55), a known in-
hibitor of the NorA MDR pump (22). Berberine was chosen
for inclusion in the hybrid because it is a NorA substrate
(12) and because it is potentially an excellent antimicrobial
capable of accumulating in bacterial cells in the absence of
MDR activity (33). Further, the antibacterial activity of ber-
berine is thought to arise from its effects on cell membranes
and through its interactions with DNA (1). Since these
mechanisms are not target specific, it is unlikely that bacte-
rial resistance to berberine could develop through target
modification.
In designing SS14, we reasoned that the berberine moiety
could elicit its antimicrobial effects while the INF55 com-
ponent concurrently inhibited MDR pumps to reduce efflux
of the hybrid. SS14 was shown to accumulate in the impor-
tant human pathogen Staphylococcus aureus (2) and to be a
more potent antibacterial than either berberine alone (15)
or berberine in combination with INF55 (32). In this report,
several properties of two new hybrids, SS14-M and SS14-P,
the 3- and 4-substituted regioisomers of SS14, respectively,
are assessed alongside those of SS14 in order to explore the
effects of varying the relative orientation of the putative
antibacterial and pump-blocking moieties in these com-
pounds.
* Corresponding author. Mailing address: School of Chemistry,
University of Wollongong, Northfields Ave., NSW 2522, Australia.
Phone: 61 (0)2 4221 5085. Fax: 61 (0)2 4221 4287. E-mail: mkelso
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† Present address: Cubist Pharmaceuticals, Lexington, MA 02421.
‡ Present address: School of Chemistry, University of New South
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Chemistry. The synthesis of SS14 has been described previously (2). The
synthesis of SS14-M and SS14-P is to be reported elsewhere (7).
Bacterial strains. The following bacterial strains were used: S. aureus 8325-4
(wild-type), K1758 (norA) (29), K2378 (norA pK374::norA; pK374::norA is a
plasmid that results in overexpression of norA from S. aureus SA1199) (17),
Enterococcus faecalis MMH594 (14), and Escherichia coli HB101.
In vitro antibacterial activity. Cells (105 ml1) were inoculated into broth and
dispensed at 50 l well1 in 384-well microtiter plates. MICs were determined in
triplicate by serial 2-fold dilution of the test compounds. The MIC was defined
as the concentration of the agent that completely inhibited cell growth during
18 h of incubation at 37°C. Growth was assayed with a microtiter plate reader
(Spectramax PLUS384; Molecular Devices) by monitoring the absorption at
600 nm.
Caenorhabditis elegans live infection model. The nematode assay was per-
formed essentially as described previously (2) with some modifications. Eggs
from gravid adult glp-4(bn2) sek-1(km4) worms (4, 35) were isolated using the
hypochlorite method and hatched at 15°C for 2 days. The resulting L1-stage
worms (n  4,000) were grown on 90-mm plates of SK-NS agar (modified
enhanced NGM [0.35% {wt/vol} peptone, 0.3% {wt/vol} Nacl, 5 g/ml choles-
terol, 1 mM CaCl2, 1mM MgSO4, 25 mM KH2PO4, 2% agar] agar medium with
62.5 U/ml nystatin and 100 g/ml streptomycin) containing lawns of E. coli
HB101. The worms were grown at 25°C for 52 h to produce sterile, young adults.
A culture of E. faecalis MMH594 was grown in brain heart infusion (BHI) broth
(BD Difco) with 80 g/ml kanamycin at 37°C for 6 h, and 100 l of the culture
was spread onto each 90-mm plate of BHI agar with 80 g/ml kanamycin. Lawns
of E. faecalis were grown at 25°C for 16 h and transferred to 15°C for 8 h. The
sterile adult worms were resuspended in M9 buffer and washed twice with M9
buffer in a 1:10 ratio to remove the E. coli cells. Approximately 8,000 worms were
pipetted onto each lawn of E. faecalis and incubated for 15 h at 15°C. Upon
infection, the worms were resuspended in M9 buffer and used as described
below. Plates (384 wells; Corning 3712) were filled with 55 l medium. Using the
Union Biometrica Copas worm sorter according to the manufacturer’s protocols,
15 of the infected worms were transferred to each well in a total volume of
approximately 15 l. The total volume per well was 70 l with (final concentra-
tions) 20% BHI, 60% M9 buffer, 80 g/ml kanamycin, 62.5 U/ml nystatin, 1%
dimethyl sulfoxide (DMSO), and 19% sheath solution (Union Biometrica). The
plates were vortexed for 5 s, centrifuged at 1,000  g for 10 s, and sealed with
gas-permeable membranes (BreathEasy; Diversified). The plates were placed in
a single layer on the top shelf of a 26.3°C incubator and incubated without
agitation for 5 days at 85% relative humidity. Using a Molecular Devices
Discovery-1 microscope with a 2 objective, bright-field transmitted light
images showing the entire well were captured as 16-bit TIFF images. These
images were converted into 8-bit JPEG images using the CellProfiler program
(www.cellprofiler.org), and the resulting images were scored manually for worm
survival by analyzing worm body positioning. Eight wells prepared with four
independent compound dilutions were analyzed for each treatment.
Bacterial cell uptake experiments. Bacterial cell uptake experiments were
performed essentially as described previously (31) with some minor modifica-
tions. Briefly, S aureus cultures were grown at 37°C until the optical density (OD;
at 600 nm) reached 1.5. The cells were pelleted by centrifugation, washed twice
with phosphate-buffered saline (PBS), and resuspended in PBS containing 10
mM dextrose to obtain an OD of 0.8. The cells were then incubated for 1 h at
37°C (with aeration) before they were washed twice with PBS (containing 10 mM
dextrose) and further diluted to an OD of 0.3 in PBS. The assay was performed
in 96-well flat-bottom white microtiter plates in a final volume of 200 l. Com-
pounds were added at a concentration of 3 M each. For the ethidium bromide
uptake experiments, the hybrid compounds or INF55 was added first. Fluores-
cence was measured using a SpectraMax Gemini XS fluorimeter (Molecular
Devices). Uptake experiments with berberine, INF55, and the SS14 hybrids were
performed at excitation and emission wavelengths of 355 and 517 nm, respec-
tively. Experiments with ethidium bromide were performed at least in triplicate
at excitation and emission wavelengths of 530 and 600 nm, respectively. The
background fluorescence for all compounds in the absence of cells was sub-
tracted from the raw data.
Ethidium bromide efflux experiments. The efflux assay was performed as
described previously with some modifications (31). NorA-overexpressing (K2378
NorA) S. aureus cells were grown at 37°C to an OD of 0.9, pelleted, washed
twice with PBS, and then resuspended in PBS to an OD of 0.8. The cells were
then loaded with 3 M ethidium bromide and 30 g/ml of reserpine and incu-
bated at 37°C for 20 min. After the cells were washed twice with ice-cold PBS,
they were added to a chilled 96-well flat-bottom black microtiter plate containing
ice-cold PBS–10 mM dextrose at an OD of 0.3 in a total volume of 200 l.
Hybrids were added before the cells to give final concentrations of 3 M. As a
negative control (i.e., no ethidium efflux), PBS (without dextrose) containing 30
g/ml of reserpine, a known efflux pump inhibitor (26), was added instead of the
SS14 hybrids. Fluorescence was measured with a SpectraMax Gemini XS appa-
ratus at excitation and emission wavelengths of 530 and 600 nm, respectively.
Molecular modeling. Hybrids were constructed using the DS Modeling 1.6
program (Accelrys, San Diego, CA, 2006), and atom types and partial charges
were assigned using the Accelrys CHARMm force field (23). The berberine
quaternary nitrogen of each hybrid was assigned a formal 1 charge. A simu-
lated annealing protocol was ported from the superseded program Insight II
(version 97.0; MSI Inc. [now Accelrys], San Diego, CA, 1997) into the DS
Modeling 1.6 program and subjected to an in-house rewrite of the annealing
scripts for use with CHARMm. Each hybrid was subjected to stepwise minimi-
zation and relaxation using the CHARMm molecular dynamics module of the
DS Modeling 1.6 program (version 29b1) program (8). The in vacuo simulation
used default nonbonding parameters (cutoff, 13.50; cutoff on, 8.00; cutoff off,
12.00). The structures were minimized using steepest descents for 3,000 steps
(gradient tolerance, 0.1) with all nonhydrogens explicitly fixed and then mini-
mized with the adopted-basis-set Newton-Raphson (ABNR) algorithm for
30,000 steps (gradient tolerance, 0.01) with no constraints. The system was
annealed for 5,000 cycles by heating to 800 K in 20 K increments (2,000 steps),
cooled to 0 K in 10 K increments (4,000 steps), and then maintained at this
temperature for 6,000 steps.
RESULTS AND DISCUSSION
In vitro antibacterial activity. Berberine is a mild antibacte-
rial that is effluxed from cells by MDR pumps, including NorA.
Deletion of norA renders bacterial cells more sensitive to ber-
berine, and overexpression of NorA increases bacterial resis-
tance to the drug. Coadministration of the NorA inhibitor
INF55 potentiates the antibacterial activity of berberine. Con-
jugating berberine to INF55 in the form of hybrid SS14 creates
an antimicrobial more potent (2) than the combination of the
two agents, as does conjugation in the form of a related hybrid
bearing a methylene ether (OCH2OO) linkage (31). We pre-
viously characterized these effects in wild-type (8325-4), NorA-
knockout (K1758 norA), and NorA-overexpressing (K2378
NorA) S. aureus cells (2, 31); and a selection of these data
are included in Table 1 to facilitate comparison with the MICs
of SS14-M and SS14-P. It is of note that the MIC for berberine
against the NorA-knockout strain decreases from 40 M when
it is administered alone to 6.25 M when it is administered
with INF55. This NorA-independent effect of INF55 suggests
that INF55 inhibits berberine-effluxing MDR pumps, in addi-
tion to NorA.
SS14, SS14-M, and SS14-P were found to have similar ac-
tivities against the three S. aureus strains (Table 1), although
SS14 showed a slightly higher potency than its isomers against
the wild-type and NorA-knockout strains. In contrast to the
MICs for berberine and berberine in the presence of INF55,
the MICs for the individual hybrids were found to be indepen-
dent of NorA activity and remained essentially unchanged
(	2-fold difference) for all three S. aureus strains. We con-
clude that SS14, SS14-M, and SS14-P are comparable antibac-
terials that are not efficiently effluxed by NorA.
Antibacterial activity in a live infection model. A simple live
infection model uses the nematode Caenorhabditis elegans as a
host for the bacterial pathogen Enterococcus faecalis (2, 24). In
this model, the gastrointestinal tract of nematodes is infected
by feeding them on lawns of E. faecalis, which leads to their
death via a multifactorial process over the course of 5 days. We
previously showed that infected nematodes can be cured with




































antibiotics that are active against E. faecalis (e.g., vancomycin)
and with SS14 (2). The worm-curing effects of SS14 have been
studied here in parallel with those of SS14-M and SS14-P in
order to compare their activities in this live infection model.
Figure 1 shows that mock (DMSO)-treated worms display a
median survival time (time to 50% lethality [LT50]) of just
under 48 h. Treatment with all three hybrids produced a sig-
nificant curative effect (P 	 0.0001 for treatments compared to
mock treatment), extending the LT50 values out beyond 110 h.
No significant difference between the effects of the three hy-
brids on worm survival was observed.
Uptake of hybrids in S. aureus cells. Berberine uptake into
microbial cells can be monitored in real time by measuring the
fluorescence increases that occur as it binds to cellular DNA
(34). This method has been used to show that berberine on its
own does not accumulate in S. aureus cells and that its uptake
increases in the presence of INF55 (2). Figure 2 shows the data
for the uptake of SS14 (31), SS14-M, and SS14-P into wild-
type, NorA-knockout, and NorA-overexpressing S. aureus
cells. Also shown for comparison are uptake data for berberine
and berberine in the presence of INF55.
Uptake of the hybrids into all three S. aureus strains was
found to be substantially greater than that of either berberine
alone or berberine in the presence of INF55. Additionally,
uptake of the individual hybrids varied little between wild-type,
NorA-knockout, and NorA-overexpressing S. aureus strains,
providing further evidence that the hybrids are not effi-
ciently effluxed by NorA. Curiously, the uptake kinetics for
SS14 were clearly distinct from those of SS14-M and SS14-P.
While uptake of SS14 showed a lag period before it reached
and maintained a maximum value, uptake of SS14-M and
SS14-P reached their maxima at the start of the experiments,
before they declined slightly and eventually leveled off.
Inhibition of MDR pumps by hybrids. Intuitively, accumu-
lation of hybrids in bacterial cells must arise either because
they inhibit the function of efflux pumps or because they are
not pump substrates. Differentiating these two effects is theo-
retically possible by comparing the uptake of berberine into S.
aureus cells in the presence or absence of hybrids. If hybrids
inhibit pumps, then berberine uptake should increase in their
presence. If hybrids are not pump substrates, then there should
be no increased berberine uptake in their presence. Previously
reported fluorescence-based methods for monitoring berber-
ine uptake into cells (34) cannot be used in these experiments,
however, due to the confounding effects of the fluorescence
arising from the hybrids interacting with cellular DNA. This
FIG. 1. Effects of hybrids SS14 (Œ), SS14-M (f), and SS14-P (F)
(at 20 M) and vancomycin () (at 8.6 M) on the survival of C.
elegans infected with E. faecalis. , mock (DMSO) treatment.
TABLE 1. MICs for SS14, SS14-M, and SS14-P against three S. aureus strainsa
S. aureus strain
MIC (M)
Berberinea Berberine  INF55a SS14 SS14-M SS14-P
8325-4 wild type 325 12.5 9.4 20.1 40.2
K1758 norA 40 6.25 9.4 20.1 20.1
K2378 NorA 
650 50 18.8 20.1 40.2
a Values were retrieved from a previous report (2). INF55 at 525 M shows no activity against these strains.




































problem can be circumvented by using ethidium bromide in
place of berberine. Like berberine, ethidium bromide is a hy-
drophobic cation and a known substrate for MDR pumps,
including NorA, NorC, MdeA, SdrM, MepA, and SepA (12,
13, 17, 18, 25, 36, 37). The fluorescence increases observed
when berberine interacts with DNA are typically measured at
an emission wavelength of 517 nm, after excitation at 355 nm.
When ethidium bromide interacts with DNA, increases in flu-
orescence are measured at the emission wavelength of 600 nm,
after excitation at 530 nm. Fluorescence increases at 600 nm
can thus be used to monitor the uptake of ethidium bromide
into cells in the presence of the berberine hybrids without the
confounding effects of hybrid/DNA fluorescence. In this sys-
tem, increases in ethidium bromide uptake in the presence of
hybrids (observed as increases in fluorescence at 600 nm)
would confirm that hybrids are MDR inhibitors and do not
simply evade the pumps.
Figure 3 shows that the presence of SS14-M and SS14-P
produced substantial increases in ethidium bromide uptake in
wild-type, NorA-knockout, and NorA-overexpressing S. aureus
cells. The fluorescence increases observed in the presence of
these two hybrids were greater in all three S. aureus strains
than the increases observed with ethidium bromide alone or
ethidium bromide in the presence of INF55. Surprisingly, the
fluorescence increases observed with SS14 were only slightly
greater than those observed with ethidium bromide alone and
lower than those produced by ethidium bromide in the pres-
ence of INF55. These results demonstrate that SS14-M and
SS14-P inhibit the set of MDR pumps responsible for ethidium
bromide efflux in S. aureus, cells while SS14 has only minimal
effects on these pumps.
Corroborating evidence that hybrids inhibit ethidium bro-
mide-effluxing MDR pumps was sought by monitoring the de-
creases in fluorescence observed over time as ethidium bro-
mide is effluxed from ethidium bromide-preloaded NorA
S. aureus cells. Inhibition of MDR pumps by hybrids in this
system is evidenced by reduced losses of fluorescence at 600
nm relative to the loss when hybrids are absent. Figure 4 shows
that the presence of SS14-M and SS14-P significantly reduced
ethidium bromide efflux. INF55 caused a lesser reduction in
ethidium bromide efflux than SS14-M and SS14-P, while only a
weak effect was observed with SS14. These results correlate
with those of the uptake experiments described above and
together confirm that SS14-M and SS14-P are MDR inhibitors
and true dual-action antibacterials, whereas SS14 has only mi-
nor inhibitory effects on MDR pumps.
Conformational analysis of SS14, SS14-M, and SS14-P by
molecular dynamics/simulated annealing. The studies de-
scribed above demonstrate that SS14, SS14-M, and SS14-P
each display very similar antibacterial activity against S. aureus
cells and in a C. elegans live infection model. Uptake of SS14
into S. aureus cells and its effects on ethidium bromide uptake
and efflux were, however, clearly distinct from those of SS14-M
and SS14-P. It was considered that the divergent properties of
SS14 might arise from a conformational preference in this
hybrid that was not prevalent in its isomers. Molecular dynam-
ics/simulated annealing experiments were thus performed to
FIG. 2. Uptake of berberine (}), berberine in the presence of INF55 (), hybrid SS14 (Œ), hybrid SS14-M (f), and hybrid SS14-P (F) into S.
aureus cells: (a) wild-type 8325-4 S. aureus cells; (b) NorA-knockout (K1758 norA) S. aureus cells; (c) NorA-overexpressing (K2378 NorA)
S. aureus cells. Uptake was measured by monitoring the increases in fluorescence at 517 nm (excitation at 355 nm) and is expressed as arbitrary
units (A.U.). All compounds were present at a concentration of 3 M. The curves are representative of at least three independent experiments.
FIG. 3. Uptake of ethidium bromide (}), ethidium bromide in the presence of INF55 (), and ethidium bromide in the presence of hybrids
SS14 (Œ) (31), SS14-M (f), and SS14-P (F) into S. aureus cells: (a) wild-type 8325-4 S. aureus cells, (b) NorA-knockout (K1758 norA) S. aureus
cells; (c) NorA overexpressing (K2378 NorA) S. aureus cells. Uptake was measured by monitoring the increases in fluorescence at 600 nm
(excitation at 530 nm) and is expressed as arbitrary units (A.U.). All compounds were present at a concentration of 3 M. Curves are representative
of at least three independent experiments.




































identify and compare the low-energy conformations of the
three isomers.
The preferred conformations identified for each isomer fell
into two distinct groups: (i) an ensemble of lowest-energy con-
formations comprising 2 to 5% of the total structures and (ii)
an ensemble of equilibrium conformations comprising 90%
of the total structures. The lowest-energy ensemble for SS14
positioned the indole plane at 90° to the plane of the benzene
ring of the INF271 moiety, which in turn was oriented orthog-
onally to the plane of the berberine component (Fig. 5a).
Importantly, the majority of the equilibrium conformations of
SS14 positioned the planar indole group of the INF55 moiety
directly over the positively charged quaternary nitrogen of
berberine, apparently being stabilized by a -stacking or cat-
ion- interaction (Fig. 5d).
The lowest-energy ensemble for SS14-M placed the indole
and benzylic groups only slightly out of plane, with this plane
being oriented at 90o to the berberine component and ex-
tended away from it (Fig. 5b). The majority of the equilibrium
conformations of SS14-M (Fig. 5e) were very similar to its
lowest-energy conformations, differing only in the puckering
of the nonaromatic berberine six-membered ring. The low-
est-energy (Fig. 5c) and equilibrium conformational (Fig.
5f) ensembles for SS14-P were essentially identical and anal-
ogous to the lowest-energy and equilibrium conformations
of SS14-M, wherein the INF55 moieties extended away from
the berberine unit.
These modeling results indicate that SS14 prefers to adopt a
more compact globular conformation that differs markedly
from the more extended conformations found in SS14-M and
SS14-P. The unique conformation for SS14 identified here may
explain why it shows different bacterial cell uptake kinetics and
reduced inhibitory effects on MDR pumps relative to those of
SS14-M and SS14-P.
In summary, SS14, SS14-M, and SS14-P were shown to be
useful probes for exploring the effects of varying the relative
positioning of the putative antibacterial and pump-blocking
moieties in berberine-INF55 hybrids. The hybrids each showed
similar MICs against three S. aureus strains expressing various
levels of NorA and identical activities in a live-animal infection
model. We conclude that all three compounds are antibacterial
agents and are not efficiently effluxed by NorA. All the hybrids
accumulated appreciably in S. aureus cells, although SS14 dis-
played uptake kinetics distinct from those of its two isomers.
SS14 also showed only minor effects on the uptake and efflux of
ethidium bromide in S. aureus cells, whereas both SS14-M and
SS14-P strongly potentiated ethidium bromide uptake and re-
duced its efflux. We conclude that all three hybrids accumulate
in bacterial cells because they are poorly effluxed by MDR
pumps but only SS14-M and SS14-P (and not SS14) also func-
tion to inhibit MDR pumps and are thus true dual-action
antibacterials. Conformational searching using molecular dy-
namics/simulated annealing showed that SS14-M and SS14-P
adopt conformations where the INF55 moiety extends away
from the berberine unit, whereas the INF55 moiety in SS14
prefers to fold back over berberine to produce a more compact
structure. The different presentation of the INF55 moiety in
SS14 is proposed as an explanation for why its properties
diverge from those of its isomers. Overall, this study demon-
strates that the structural and conformational variations arising
from subtle repositioning of the pump-blocking INF55 moiety
in berberine-INF55 hybrids have minimal effects on their an-
tibacterial activities but can significantly alter their effects on
MDR pumps.
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mational ensembles of SS14 (a), SS14-M (b), and SS14-P (c) and the
equilibrium conformational ensembles of SS14 (d), SS14-M (e), and
SS14-P (f). Structures were calculated using a molecular dynamics/
simulated annealing protocol in DS Modeling 1.6 (Accelrys).
FIG. 4. Efflux from NorA-overexpressing (K2378 NorA) S. au-
reus cells of ethidium bromide (}); ethidium bromide in the presence
of INF55 (); and ethidium bromide in the presence of hybrids SS14
(Œ) (31), SS14-M (f), and SS14-P (F). Cells were initially preloaded
with ethidium bromide in the presence of the MDR inhibitor reserpine
(26) to prevent the loss of ethidium bromide. Hybrids or INF55 in
dextrose buffer was added to the cells after they had been washed to
remove the reserpine. Efflux was measured by monitoring the de-
creases in fluorescence at 600 nm (excitation at 530 nm) and is ex-
pressed as arbitrary units (A.U.). All compounds were present at a
final concentration of 3 M. The graph is representative of at least
three independent experiments. Berberine alone had no effect on
ethidium bromide efflux (data not shown).
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